Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy

• DOI: 10.21203/rs.2.22832/v2
• Publication Date: 2020-04-01T10:42:34Z
• Authors: Mohammad Ismail; Sehrash Khan; Fahadullah Khan; Sidra Noor; Hira Sajid; Shazia Yar; Irum Rasheed
• Keywords: Concomitant

Abstract Background: Cancer patients often receive multiple drugs to maximize their therapeutic benefit, treat co-morbidities and counter the adverse effects of chemotherapy. Concomitant administration increases risk drug interactions leading compromised efficacy or safety therapy. The purpose this study was identify prevalence, levels predictors potential drug-drug (pDDIs) among cancer patients. Methods: Six hundred seventy-eight receiving chemotherapy from two tertiary care hospitals were included in cross-sectional study. Patient medication profiles screened for pDDIs using Micromedex® database. Logistic regression analysis performed pDDIs. Results: overall prevalence 78%, majority had 1-2 (39.2%). A total 1843 detected. Major-pDDIs most frequent (67.3%) whereas, a significant association found between >7 all prescribed (p <0.001) ≥3 anti-cancer <0.001). Potential outcomes these include reduced effectiveness, QT interval prolongation, tendon rupture, bone marrow suppression neurotoxicity. Conclusions: Major finding is high signifying need strict patient monitoring Patients at higher those with any types anticancer drugs. Moreover, list frequently identified major moderate will aid health professional timely identification prevention